



Regional: OrbiMed Asia Partners III

Project Name	OrbiMed Asia Partners III
Project Number	51072-001
Borrower/Company	OrbiMed Asia Partners III, L.P.
Country	RegionalIndiaChina, People's Republic of
Location	China - Nation-wide; India - Nation-wide
Approval Number	7516
Type of ADB Assistance / Amount	Ordinary capital resources USD 60.00 million Proposed
Strategic Agendas	Inclusive economic growth
Drivers of Change	Governance and capacity development Private sector development
Sector / Subsector	Finance - Infrastructure finance and investment funds Health - Health care finance
Gender Equity and Mainstreaming	No gender elements
Responsible ADB Department	Private Sector Operations Department
Responsible ADB Division	Private Sector Investment Funds & Special Initiatives Div
Responsible ADB Officer	Mahmud, Farshed
Project Sponsor(s)	OrbiMed Asia GP III, L.P.
Description	ADB's proposed investment in OAP III is a continuation of its strategy to increase the pace of PSOD investments in health care, as well as an endorsement of OrbiMed as the preferred fund manager given its track record and competitive positioning in the People's Republic of China (PRC) and India, two of Asia's fastest growing health care markets. OAP III will continue to focus its investment activity on companies that benefit from three primary drivers which, according to OrbiMed's in-depth market research, are creating compelling opportunities for private equity investors in Asia: (i) improving affordability and quality in the delivery of health care products and services, particularly for the largely underserved Asian consumers; (ii) increasing efficiency in the accessibility and use of health care services outside of major urban cities in Asia; and (iii) leveraging Asia's cost advantage and local strengths for the region and globally.
Objectives and Scope	The Fund will target primarily growth equity investments in companies across the healthcare industry, including pharmaceuticals, biotechnology, medical devices, healthcare services and digital health. A majority of these investments is expected to focus on the rapidly growing demand for higher quality, affordable healthcare in the People's Republic of China (PRC) and India with export opportunities to other Asian markets, and with a small pocket of opportunistic investments in Southeast Asia.
Linkage to Country/Regional Strategy	The GP's investment strategy for OAP III will be similar to that of the previous fund. The Fund will continue to focus its investment activity in companies that benefit from primarily three drivers, which OrbiMed believes create compelling opportunities for PE investment: (1) increasing affordability, accessibility and quality in the delivery of healthcare products, particularly for the underserved Asian consumers; (2) increasing efficiency in the accessibility and use of healthcare services outside of Asian mega-cities; and (3) leveraging Asia's cost advantage and local strengths.

Safeguard Categories

Environment	FI
Involuntary Resettlement	FI-C
Indigenous Peoples	FI-C

Summary of Environmental and Social Aspects

Environmental Aspects	The proposed OAP III transaction is categorized as FI and Fund's investee companies is expected to be classified as category B. OAP III will prohibit a company from marketing or distributing a pharmaceutical product in a jurisdiction where its consumption and/or sale have been banned, withdrawn, or rejected by the Government. For guidance, OAP III will utilize the United Nations Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments and/or bi-annual updates prepared by the World Health Organization on pharmaceuticals, an input to the cited UN Consolidated List. The ESMS will apply key provisions in and make reference with the World Bank Group Environmental, Health and Safety Guidelines for Health Care Facilities, and Pharmaceuticals and Biotechnology Manufacturing; (ii) the American Institute of Architects and the Facility Guidelines Institute, the American Society for Healthcare Engineering of the American Hospital Association, and (iii) the Green Guide for Health Care (www.gghc.org).
Involuntary Resettlement	The Fund will adopt an environment and social management system commensurate with the level of potential risks of its investments. This will include screening procedures for categorizing projects based on ADB Safeguards Policy Statement (2009) requirements to exclude investments having impacts on involuntary resettlement.
Indigenous Peoples	The Fund will adopt an environment and social management system commensurate with the level of potential risks of its investments. This will include screening procedures for categorizing projects based on ADB Safeguards Policy Statement (2009) requirements to exclude investments having impacts on indigenous peoples.
Stakeholder Communication, Participation, and Consultation	The environment and social due diligence will include an assessment of the investee companies' stakeholder engagement activities.

Timetable for assistance design, processing and implementation

Concept Clearance	29 Mar 2017
Due Diligence	
Credit Committee Meeting	15 Jun 2017 to 15 Jun 2017
Approval	25 Aug 2017
Last PDS Update	13 Oct 2017

Project Page	https://www.adb.org/projects/51072-001/main
Request for Information	http://www.adb.org/forms/request-information-form?subject=51072-001
Date Generated	09 November 2018

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.